According to our new research study on "Minimally Invasive Surgery Robot Market Forecast to 2031 - Global Analysis - by Product and Services, Application, and End Use," the market is expected to grow from US$ 11.16 billion in 2024 to US$ 29.13 billion by 2031; it is estimated to record a CAGR of 14.8% from 2025-2031. Key factors driving the growth of the minimally invasive surgery robot market are the growing number of microsurgeries and the increasing prevalence of chronic diseases. However, the high cost of robotic systems hinders the market's growth.

The scope of the minimally invasive surgery robot market report includes the assessment of the market performance in North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa. Asia Pacific is anticipated to register the fastest CAGR in the minimally invasive surgery robot market from 2025 to 2031. The market growth in the region is attributed to an increasing aging population, rising prevalence of chronic diseases, new product development, and international players entering the region. In addition, the market in Asia Pacific is expanding due to a confluence of technological, demographic, economic, and infrastructural factors. Technological advancements, such as the integration of artificial intelligence, machine learning, and enhanced imaging systems, have significantly improved the precision and safety of robotic-assisted surgeries. This has led to increased adoption among healthcare providers and patients seeking reduced recovery times and minimized surgical risks, supporting the minimally invasive surgery robot market growth in the Asia Pacific. Also, the rising disposable incomes and government investments in healthcare infrastructure are facilitating the acquisition of costly robotic systems, making advanced surgical options more accessible.

China, India, and Japan are three significant contributors to the market growth in this region. China is expected to be the largest market for minimally invasive surgery robot in Asia Pacific. The country is observing a rise in new product approvals and a growth in the preference for robotic surgeries by healthcare professionals. For instance, in November 2023, Johnson and Johnson MedTech's Monarch platform and Monarch bronchoscope obtained regulatory approval in China. This approval makes Monarch the first minimally-invasive, robotic-assisted technology approved for peripheral lung procedures in China and the first Johnson and Johnson MedTech robotic-assisted technology to receive approval in China. This regulatory nod also marks the first such milestone for Monarch outside the US.

Companies in China are developing surgical robots to challenge the dominance of the US based Intuitive Surgical's da Vinci systems, in line with the government's push to localize the medical industry. For instance, in June 2023, Weigao Group developed a robot-assisted laparoscopic surgical system that is operated using 3D glasses.

Government and private organizations give funding for the adoption of surgical robotic systems. For instance, in June 2024, Shanghai-based Ronovo Surgical announced that it closed a Series B funding round worth US$ 44 million to support its modular robotic system. Therefore, the need for surgeries has increased in China, bolstering the demand for surgical robots and aiding the minimally invasive surgery robot market growth.

Furthermore, a number of RAS are gaining popularity in Japan. For instance, according to the article "Current status of robotic surgery in Japan gynecologic field," published in Intelligent Surgery Journal in March 2023, more than 450 units had been installed by 2022 since the first introduction of Da Vinci in Japan in 2009. There are ~1800 highly acute care hospitals in Japan, and more than 80% of the top 500 facilities have adopted the system, supporting the minimally invasive surgery robot market in Japan. Approvals for surgical robots are increasing in Japan, which is expected to contribute to the minimally invasive surgery robot market growth. For instance, in September 2022, Intuitive announced that Japan's Ministry of Health, Labour and Welfare (MHLW) cleared the da Vinci SP surgical system for use in general surgeries, thoracic surgeries (excluding cardiac procedures and intercostal approaches), gynecological surgeries, trans-oral head and neck surgeries, and urologic surgeries. Similarly, In April 2024, Medicaroid Corporation received regulatory approval from the MHLW for the Hinotori Surgical Robot System to be used in thoracic surgery.

Moreover, in April 2018, Japan introduced insurance coverage for 12 robotic surgeries. Seven new procedures were included in 2020, and eight more in 2022. As of January 2023, 29 surgeries are covered by insurance. Insurance coverage has led to an increase in the RAS in recent years in Japan, and it is driving the minimally invasive surgery robot market.

Robotic-assisted surgeries (RAS) in India have contributed significantly to the Indian healthcare industry. It has gained advancement particularly in urology and in other surgical specialties such as gynecologic surgery, prostate surgery, and joint surgery. ~500 robotic surgeons are using da Vinci systems, and ~70 da Vinci systems have been installed in various government and private hospitals such as Fortis, Apollo, Columbia Asia, and Tata Memorial.

The adoption of robotic surgeries is growing in India. In November 2023, SS Innovations International, Inc. announced the completion of 500 robotic surgeries using the company's innovative SSi Mantra Surgical Robotic System. Further, the adoption of innovative products, techniques, and technologies is expected to increase the market growth of surgical robots in India. The designer and manufacturer of da Vinci Robotic surgical systems, Intuitive Surgical, has collaborated with AIIMS Delhi to launch Robotic onboarding training (ROPE) to train the surgeons. Intuitive Surgical has installed ~73 RAS in India.

Similarly, the launch of advanced robotic systems is driving market growth in India. In June 2024, Meril (a medical device company based in India) launched an indigenously developed surgical robot called 'MISSO' for knee replacement surgeries. Furthermore, in June 2024, SS Innovations launched SSI Mantra 3, India's first Indigenous surgical robotic system. The company aims to make advanced robotic surgeries cost-effective and accessible globally. Thus, increasing acceptance of RAS among surgeons and patients in India is expected to drive the market growth of surgical robots in the country. Therefore, the factors mentioned above are promoting a favorable environment for the minimally invasive surgery robot market in the region.

Johnson and Johnson; Stryker Corp.; Medtronic Plc; Intuitive Surgical Inc.; Asensus Surgical Inc.; Smith and Nephew Plc.; Zimmer Biomet Holdings Inc.; CMR Surgical Ltd; Moon Surgical; and Curexo, Inc. are among the leading companies profiled in the minimally invasive surgery robot market report.

Based on product and services, the minimally invasive surgery robot market is segmented into robotic systems, instruments and accessories, and services. By application, the market is categorized into general surgery, gynecological surgery, urological surgery, neurosurgery, orthopedic surgery, and others. In terms of end use, the minimally invasive surgery robot market is segmented into hospitals, ambulatory surgery centers, and others. Geographically, the market is categorized into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), the Middle East and Africa (Saudi Arabia, South Africa, UAE, and Rest of Middle East and Africa), and South and Central America (Brazil, Argentina, and Rest of South and Central America).

Contact Us
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com